Business Wire

HCL Group and UpLink Announce Winners of ‘Tackling Water Pollution Challenge’ Under the Aquapreneur Innovation Initiative

21.1.2025 17:18:00 EET | Business Wire | Press release

Share

HCL Group, a leading global conglomerate, and UpLink, the World Economic Forum’s early-stage innovation initiative, have announced the winners of the 'Tackling Water Pollution Challenge,’ the third in a series of five challenges under the five-year, CHF 15 million Aquapreneur Innovation Initiative launched by HCL Group. The announcement marks a significant step in the ongoing mission to address global water challenges through groundbreaking innovation and entrepreneurship.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250121986084/en/

Roshni Nadar Malhotra, Chairperson of HCL Group, announces the winners of ‘Tackling Water Pollution Challenge’ under the Aquapreneur Innovation Initiative in Davos. (Photo: Business Wire)

After evaluating over 270 submissions from around 60 nations, 10 Aquapreneurs from 9 countries were chosen for their innovative solutions in the freshwater sector. This year’s winners, termed ‘UpLink Top Innovators and Aquapreneurs’, reflect a diverse set of expertise demonstrating the transformative potential of innovation in tackling water pollution worldwide. The winners will share financial award from a pool of CHF 1.75 million, enabling them to scale their initiatives and amplify their impact. In addition to funding, the winners will also gain access to exclusive resources, mentorship, and global networks provided by HCL Group and UpLink.

The Tackling Water Pollution Challenge was dedicated to addressing freshwater issues worldwide, with special focus on combating water pollution. Solutions presented by winners included cutting-edge advancements in filtration systems, wastewater treatment, industrial water reuse, and water quality monitoring technologies.

Highlighting the role of Aquapreneur Innovation Initiative in combating challenges related to freshwater, Roshni Nadar Malhotra,Chairperson of HCL Group, said: “Water scarcity and pollution are existential threats to humanity and biodiversity. The Aquapreneur Innovation Initiative launched a couple of years ago aims to discover and support the most innovative start-ups and scale-ups tackling the world’s most pressing water issues. The 20 pioneering start-ups, winners of the previous two years, have collectively gone on to achieve immense success. In 2024 alone, they helped save over 12 billion litres of water, equivalent to Switzerland’s entire water footprint each year. They also treated 3 billion litres of wastewater. The Grant provided by HCL enabled them to expand to new markets, deploy pilot projects, increase customer count, and scale-up production and operations. These 20 start-ups have raised US$70 million in funding since joining the Initiative. So, congratulations to all ten of this year’s winners. I’m already looking forward to returning to Davos next year to share their successes!”

Added Olivier Schwab, Managing Director of the World Economic Forum, “As water challenges grow more urgent, HCL Group and UpLink’s continued commitment underscores the need for collaborative innovation to safeguard freshwater ecosystems. The initiative is not just driving immediate solutions, investment and multistakeholder partnerships —it is paving the way for a sustainable future where clean, accessible water is a reality for all. By supporting bold, scalable solutions, we are making a critical contribution to addressing one of the most significant global challenges of our time. The collaboration between HCL Group and UpLink continues to set a global benchmark for how innovation can drive large-scale, lasting change.”

Water pollution is a global challenge, with about 80% of the world's untreated wastewater being released into rivers, lakes, and oceans. This leads to 485,000 premature deaths every year worldwide and costs the global economy $260 billion annually. The challenge of water pollution intensifies as countries industrialize, with chemical contamination of freshwater sources being prominent across industrial economies. This includes the rise of microplastics and PFAS (Per- and polyfluorinated alkyl substances), also known as the Forever Chemicals in water supplies, risking public health.

The 2025 Tackling Water Pollution Challenge Winners

  • Aquagga, United States of America, focuses on innovative PFAS destruction using its Hydrothermal Alkaline Treatment (HALT) technology for environmental remediation and wastewater treatment.
  • Digital Paani, India, focuses on enhancing operational excellence in water treatment, addressing water scarcity and pollution through scalable solutions in under-resourced areas.
  • Fluidion, France, advances water intelligence with innovative sampling solutions that monitor pollution and water quality across urban, natural, and industrial environments.
  • FREDsense, Canada, provides in-field lab-based water quality testing solutions, empowering utilities and environmental consultants with real-time, accurate data for effective water management.
  • Fungi Life, Colombia, uses fungal biotechnology to create sustainable ingredients, aiming for net-zero emissions by revalorizing agro-industrial waste for environmental sustainability.
  • Mimbly, Sweden, optimizes water resources in the laundry industry through innovative recycling and filtration solutions, promoting sustainability with advanced water-saving technologies.
  • Oxyle, Switzerland, offers an economical, sustainable solution to PFAS contamination by completely eliminating PFAS from water, empowering industrial and environmental remediation companies to tackle contamination effectively.
  • SENTRY, Canada, is a biological activity and water quality monitoring platform that uses unique bio-electrode sensor technology for real-time microbial performance monitoring in wastewater treatment systems.
  • Syrinx, Australia, offers innovative water treatment solutions with its nature-based 'Wetland-in-a-Box'® (EnPhytoBox), addressing water pollution and boosting climate resilience, especially in agriculture.
  • WASE, United Kingdom, treats industrial wastewater onsite, helping customers comply with regulations, maximize bioenergy generation, and decarbonize thermal energy demands through sustainable, economically viable solutions.

In addition to the financial awards, the winners will have the opportunity to participate in events and projects led by the World Economic Forum and its partners. These opportunities will provide invaluable support to scale their ventures, ensuring sustainable and impactful solutions for water challenges.

Since its inception, the Aquapreneur Innovation Initiative has made notable progress in addressing global freshwater challenges. This funding has enabled winners to innovate, scale production, and expand into new markets. The initiative has also driven progress in water conservation, wastewater treatment, greenhouse gas emission reductions, and job creation. To date, top innovators have cumulatively raised over $70 million in funding to scale their innovations.

HCL Group and UpLink’s ongoing collaboration underscores their shared commitment to sustainability and innovation, paving the way for a future where freshwater resources are managed responsibly and effectively.

Notes to the editor

About UpLink

UpLink is the World Economic Forum’s early-stage innovation initiative that builds ecosystems that enable purpose-driven, early-stage entrepreneurs to scale their business for the markets and economies that are essential for a net-zero, nature-positive, equitable future.

Sourcing innovations through a competition framework known as innovation challenges, UpLink has run more than 50 challenges to date and selected over 500 early-stage entrepreneurs with innovative solutions across critical SDG areas including freshwater, health, food, ocean, plastics, education, climate and more.

For more information, visit https://uplink.weforum.org

About HCL Group:

Founded in 1976 as one of India’s original IT garage start-ups, HCL Group is a pioneer of modern computing with many firsts to its credit, including the introduction of the 8-bit microprocessor-based computer in 1978 well before its global peers. Today, the HCL Group has a presence across varied sectors that include technology, healthcare and talent management solutions and comprises three companies – HCL Infosystems, HCLTech and HCL Healthcare. The enterprise generates annual revenues of over US$13.8 billion with 220,000 employees operating across 60 countries. For further information, visit www.hcl.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250121986084/en/

Contacts

For further information, please contact:


Shruti Saxena: shruti-saxena@hcl.com (9654356487)
Alisha Bisherwal: Alisha.a@hcl.com (8447821231)

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Quantum Computer Goes Live at Supercomputing Center CINECA in Italy, Boosting National Compute Infrastructure and Research11.6.2026 15:50:00 EEST | Press release

The Italian Research Centre on High Performance Computing, Big Data, and Quantum Computing (ICSC) today inaugurated the IQM Radiance 54 quantum computer at CINECA, one of Europe's leading supercomputing centers, enabling advanced applications in optimization, simulation, and machine learning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611898215/en/ The moment Italy's second IQM quantum computer went live at CINECA in Bologna. IQM has previously announced its ongoing business combination with Real Asset Acquisition Corp (Nasdaq: RAAQ), which will result in IQM becoming a public company in mid-2026. The installation, located at the CINECA headquarters in the DAMA Tecnopolo in Bologna, represents not just technological progress but a strategic Italian asset providing concrete tools for the scientific community and businesses to foster innovation, accelerate research, and transform knowledge into high-impact applications.

Wyss Geneva Steps Into Its Next Chapter11.6.2026 14:33:00 EEST | Press release

The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simultaneously building a robust pipeline of next-generation programs in AI-guided neuromodulation and min

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 14:24:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: "While the median age of diagnosis for CLL is 70 and the average age of treatment initiation is 75, many pivotal trials still underrepresent the patients that physicians most often see in practice. These data show that the durable benefit of

Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 14:00:00 EEST | Press release

Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction. GreensLedge Capital Markets advised the seller. About Clearlake Clearlake Capital is a leading global alternative a

Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 14:00:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrated statistical superiority over deucravacitinib for all key secondary endpoints, including PASI 90 response and Static Physician's Global Assessment (sPGA) 0 at week 16. Zasocitinib was generally well tolerated with a consistent safety and tolerability profile and no new safety signals identified. Perspectives on head-to-head zasocitinib study “In this head-to-head study, zasocitinib clearly demonstrated

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye